Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, Matinas BioPharma Holdings, Inc. reported revenue of $1M, down 65.6% year over year. Operating margin was -2168.4% and net margin -2093.2%, on a free-cash-flow margin of -1413.9% with capital expenditure at 19.9% of revenue. Every figure is computed directly from MTNB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $1M | -2168.4% | -2093.2% |
| FY2022 | $3M | -771.3% | -658.6% |
| FY2021 | $0M | -74954.5% | -70554.5% |
| FY2020 | $0M | -15288.4% | -14177.0% |
How does MTNB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.